Calidi Biotherapeutics
CLDI
19 hedge funds and large institutions have $363K invested in Calidi Biotherapeutics in 2024 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 17 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
0.02% more ownership
Funds ownership: 0% → 0.02% (+0.02%)
31% less capital invested
Capital invested by funds: $523K → $363K (-$160K)
34% less funds holding
Funds holding: 29 → 19 (-10)
59% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 17
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCC
Cable Car Capital
San Francisco,
California
|
+$119K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$57.3K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$34.2K |
| 4 |
AMH
Apollo Management Holdings
New York
|
+$18.1K |
| 5 |
EWM
Evermay Wealth Management
Arlington,
Virginia
|
+$9.19K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCI
RS Crum Inc
Newport Beach,
California
|
-$52.7K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$25.2K |
| 3 |
RWI
Red Wave Investments
Dillsburg,
Pennsylvania
|
-$23.1K |
| 4 |
HF
HRT Financial
New York
|
-$20K |
| 5 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$18.9K |
CLDI Hedge Fund Activity: Q3 2024 in Review
19 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in Calidi Biotherapeutics (CLDI) for Q3 2024, worth a combined $363K — down 31% from $523K a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of CLDI and 7 opened new positions — a net loss of 10 holders — while 1 trimmed existing stakes and 3 added.
The largest buyer was Cable Car Capital, adding an estimated $119K. The largest seller was RS Crum Inc, exiting entirely with an estimated $52.7K sold.
- 19 institutional investors held Calidi Biotherapeutics (CLDI) as of Q3 2024, down from 29 in Q2 2024.
- Funds reported $363K of Calidi Biotherapeutics stock for Q3 2024, down 31% quarter-over-quarter.
- 7 funds opened new Calidi Biotherapeutics positions in Q3 2024 and 17 closed out, a net change of -10 holders.
- The largest Calidi Biotherapeutics buyer in Q3 2024 was Cable Car Capital, an estimated $119K added.
- The largest Calidi Biotherapeutics seller in Q3 2024 was RS Crum Inc, an estimated $52.7K sold.
Based on aggregated 13F filings for Q3 2024.